Trial Profile

Phase I trial evaluating ACCG-2671

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACCG 2671 (Primary)
Indications Obesity
Focus Adverse reactions; First in man

Most Recent Events

27 Feb 2026 According to Structure Therapeutics media release, Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 expected in 2H 2026.
17 Dec 2025 Status changed from planning to recruiting.
06 Aug 2025 According to Structure Therapeutics media release, company plans to initiate a first-in-human Phase 1 clinical study by year-end 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com